Acne treatments: future trajectories.
Acne Vulgaris
/ drug therapy
Administration, Oral
Administration, Topical
Age Factors
Environmental Pollution
/ adverse effects
Female
Humans
Insulin Resistance
/ physiology
Insulin-Like Growth Factor I
/ drug effects
Life Style
Male
Medical History Taking
/ statistics & numerical data
Microbiota
/ drug effects
Probiotics
/ administration & dosage
Propionibacterium acnes
/ drug effects
Quality of Life
Secondary Prevention
/ methods
Stress, Psychological
/ complications
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
04
03
2020
accepted:
24
03
2020
pubmed:
16
5
2020
medline:
29
7
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
Current acne treatments present several limitations, posing the need for new effective therapies for long-term administration for recalcitrant or relapsing acne. Key players in acne that may emerge as targets for future acne treatments include the cutaneous loss of diversity of Cutibacterium (formerly Propionibacterium) acnes phylotypes and the insulin-like growth factor-1 signalling pathway. New data about the loss of diversity of microbiota in acne provides the rationale for the potential use of oral or topical probiotics. Another therapeutic approach to modulate the microbiota could be topical formulation of C. acnes bacteriophages to target specifically the pathogenic 'acnegenic' C. acnes phylotypes. Insulin-sensitizing agents such as metformin, myo-inositol and d-chiro-inositol represent promising agents, but to date there have been only limited studies and much heterogeneity in the methods of assessing acne efficacy outcomes. Moving towards a holistic approach for patients with acne is the future, by taking into account both internal and external factors, such as pollution, stress, acne family history, age, smoking habits and diet, and addressing quality of life and the psychological impact of acne.
Substances chimiques
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
955-961Informations de copyright
© 2020 British Association of Dermatologists.
Références
Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al. Quality of life measurement in acne. Position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2018; 32: 194-208.
Moradi Tuchayi S, Makrantonaki E, Ganceviciene R et al. Acne vulgaris. Nat Rev Dis Primers 2015; 1: 15029.
Zouboulis CC, Dessinioti C, Tsatsou F, Gollnick HPM. Anti-acne drugs in phase 1 and 2 clinical trials. Expert Opin Investig Drugs 2017; 26: 813-23.
Nast A, Dreno B, Bettoli V et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol 2016; 30: 1261-8.
Dessinioti C, Katsambas A. Propionibacterium acnes and antimicrobial resistance in acne. Clin Dermatol 2017; 35: 163-7.
Chien AL, Tsai J, Leung S et al. Association of systemic antibiotic treatment of acne with skin microbiota characteristics. JAMA Dermatol 2019; 155: 425-34.
Levy RM, Huang EY, Roling D et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003; 139: 467-71.
Whitehouse H, Solman L, Eady EA, Layton AM. Oral antibiotics in acne: a retrospective single-centre analysis of current prescribing in primary care and its alignment with the national antibiotic quality premium. Br J Dermatol 2019; 181: 1341-2.
Fitz-Gibbon S, Tomida S, Chiu BH et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol 2013; 133: 2152-60.
Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Research 2018; 7: 1953.
Dagnelie MA, Corvec S, Saint-Jean M et al. Decrease in diversity of Propionibacterium acnes phylotypes in patients with severe acne on the back. Acta Derm Venereol 2018; 98: 262-7.
Paugam C, Corvec S, Saint-Jean M et al. Propionibacterium acnes phylotypes and acne severity: an observational prospective study. J Eur Acad Dermatol Venereol 2017; 31: e398-9.
Saint-Jean M, Corvec S, Nguyen JM et al. Adult acne in women is not associated with a specific type of Cutibacterium acnes. J Am Acad Dermatol 2019; 81: 851-2.
Dagnelie MA, Corvec S, Saint-Jean M et al. Cutibacterium acnes phylotypes diversity loss: a trigger for skin inflammatory process. J Eur Acad Dermatol Venereol 2019; 33: 2340-8.
Wang Y, Hata TR, Tong YL et al. The anti-inflammatory activities of Propionibacterium acnes CAMP factor-targeted acne vaccines. J Invest Dermatol 2018; 138: 2355-64.
Yu Y, Dunaway S, Champer J et al. Changing our microbiome: probiotics in dermatology. Br J Dermatol 2020; 182: 39-46.
Dagnelie MA, Montassier E, Khammari A et al. Inflammatory skin is associated with changes in the skin microbiota composition on the back of severe acne patients. Exp Dermatol 2019; 28: 961-7.
Fabbrocini G, Bertona M, Picazo O et al. Supplementation with Lactobacillus rhamnosus SP1 normalises skin expression of genes implicated in insulin signalling and improves adult acne. Benef Microbes 2016; 7: 625-30.
Jung GW, Tse JE, Guiha I, Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg 2013; 17: 114-22.
Kim J, Ko Y, Park YK et al. Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris. Nutrition 2010; 26: 902-9.
AOBiome Therapeutics. Press release. AOBiome Therapeutics reports positive efficacy results from phase 2b clinical trial of ammonia oxidizing bacteria (AOB) for the treatment of acne vulgaris. Available at: https://www.aobiome.com/pressreleases/aobiome-therapeutics-reports-positive-efficacy-results-from-phase-2b-clinical-trial-of-ammonia-oxidizing-bacteria-aob-for-the-treatment-of-acne-vulgaris/ (accessed 5 January 2020).
Cardenas-de la Garza JA, Haidari W, Feldman SR. Microbiome, probiotics and dermatology. Br J Dermatol 2020; 182: 8-9.
Mirdamadi Y, Thielitz A, Wiede A et al. Insulin and insulin-like growth factor-1 can modulate the phosphoinositide-3-kinase/Akt/FoxO1 pathway in SZ95 sebocytes in vitro. Mol Cell Endocrinol 2015; 415: 32-44.
Isard O, Knol AC, Aries MF et al. Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis and induces keratinocyte proliferation. J Invest Dermatol 2011; 131: 59-66.
Fruzzetti F, Perini D, Russo M et al. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 2017; 33: 39-42.
Robinson S, Kwan Z, Tang MM. Metformin as an adjunct therapy for the treatment of moderate to severe acne vulgaris: a randomized open-labeled study. Dermatol Ther 2019; 32: e12953.
Fabbrocini G, Izzo R, Faggiano A et al. Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. Clin Ep Dermatol 2016; 41: 38-42.
Baillargeon JP, Nestler JE, Ostlund RE et al. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008; 23: 1439-46.
Unfer V, Nestler JE, Kamenov ZA et al. Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol 2016; 2016: 1849162.
Zacche MM, Caputo L, Filippis S et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009; 25: 508-13.
Advani K, Batra M, Tajpuriya S et al. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study. J Obstet Gynaecol 2020; 40: 96-101.
Dessinioti C, Platsidaki E, Zisimou C et al. A cross-sectional study of the perceptions about triggering factors in acne patients. J Eur Acad Dermatol Venereol 2018; 32: e137-9.
Dreno B, Bettoli V, Araviiskaia E et al. The influence of exposome on acne. J Eur Acad Dermatol Venereol 2018; 32: 812-19.
Dreno B, Bagatin E, Blume-Peytavi U et al. Female type of adult acne: physiological and psychological considerations and management. J Dtsch Dermatol Ges 2018; 16: 1185-94.